Sunho Biologics, Inc

IPO Hong Kong

Sunho Biologics, Inc. is a biopharmaceutical company specializing in the development and commercialization of immunotherapies, including immunocytokines, to treat cancers and autoimmune diseases. Their innovative products aim to provide affordable medicine and overcome current treatment limitations for patients worldwide.

Sharlife Shariah Status

IPO Analysis

IPO Allocation Shares

Allocation	Shares	%
Hong Kong Offer
International Offer

Company P/E ratio

Peers	P/E

Checklist	Remarks
Revenue

Premium Content

This section is available exclusively for Sharlife subscribers. Unlock access to detailed IPO analysis, financial ratios, and comprehensive reports.

View Pricing Plans

Risk Disclosure: Sharlife is a registered Shariah Advisor with the Securities Commission Malaysia. Content is for educational purposes only and does not constitute financial advice. Investments in stocks and crypto assets carry inherent risks, including loss of capital. Past performance is not indicative of future results. Shariah compliance does not guarantee returns. Please consult a licensed financial planner before making investment decisions.

	-	31/12/2022	31/12/2023	% Growth
Revenue
Other Income
Interest Income
Profit After Tax
PAT Margin %

	-	31/12/2022	31/12/2023	% Growth
Non-current Assets
Current Assets
Non Current Liabilities
Current Liabilities
Deferred Liabilities
Total Assets
Total Liabilities

	-	31/12/2022	31/12/2023	% Growth
Share Capital
Retained Earnings
Reserves
Working Capital
Shareholder Fund

0 = Lowest \| 5 = Highest
	-	-	31/12/2022	Score	31/12/2023	Score	% Growth
Current Ratio (Liquidity)
Debt Ratio (Leverage)
Gearing Ratio (Leverage)
Return on Capital Employed
Total Assets Turnover

Share Your Feedback

Sunho Biologics, Inc

Sharlife Shariah Status

IPO Analysis

Premium Content